10 research outputs found
William Potts Dewees (1768-1841) of Pennsylvania: pioneer of perinatal medicine in America.
The Importance of Nutrition in the Management of Patients with Carcinoma of the Colon and Rectum
Can Interrogation of Tumour Characteristics Lead us to Safely Omit Adjuvant Radiotherapy in Patients with Early Breast Cancer?
Adjuvant radiotherapy after breast-conserving surgery has been an important component of the standard of care for early breast cancer. Improvements in breast cancer care have resulted in a substantial reduction in local relapse rates over recent decades. Although the proportional benefits of adjuvant radiotherapy are similar for different prognostic risk groups of patients, the absolute benefits depend on the risk of relapse and therefore vary considerably between prognostic groups. Radiotherapy is not without risk and for some patients at very low risk of relapse the risks of radiotherapy may outweigh the benefit, leading to potential overtreatment. Randomised controlled trial (RCT) evidence shows that omission of radiotherapy in low risk early breast cancer does not reduce overall survival or increase breast cancer mortality and local recurrences are salvageable. Despite this there has not been a change in practice regarding omission of radiotherapy. The reasons for this may include challenges in patient selection. Recent advances in immunohistochemistry and genomic profiling may improve risk stratification and the development of biomarkers to directed therapies. Several RCTs have quantified the benefit of radiotherapy in reducing local relapse. Where a treatment benefit is known but is considered to be so small not to be clinically relevant then alternatives to RCTs may be considered to answer the question of need. This is because we can assess risk against a fixed 'absolute' boundary rather than needing a randomised comparator. The prospective cohort study is an alternative to the RCT design to answer the question of need for radiotherapy. The feasibility of recruitment into biomarker-directed de-escalation studies will become apparent as more studies open. The challenge is to determine if we are able to accurately risk stratify patients and avoid unnecessary toxicity, thereby tailoring the need for adjuvant breast radiotherapy on an individual patient basis. (C) 2018 The Royal College of Radiologists. Published by Elsevier Ltd
Relationship between hepatic hemodynamics and biliary pressure in dogs: Its significance in clinical shock following biliary decompression
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
Background In early breast cancer, variations in local treatment that substantially affect the risk of locoregional
recurrence could also affect long-term breast cancer mortality. To examine this relationship, collaborative metaanalyses
were undertaken, based on individual patient data, of the relevant randomised trials that began by 1995.
Methods Information was available on 42 000 women in 78 randomised treatment comparisons (radiotherapy vs no
radiotherapy, 23 500; more vs less surgery, 9300; more surgery vs radiotherapy, 9300). 24 types of local treatment
comparison were identified. To help relate the effect on local (ie, locoregional) recurrence to that on breast cancer
mortality, these were grouped according to whether or not the 5-year local recurrence risk exceeded 10% (�10%,
17 000 women; �10%, 25 000 women).
Findings About three-quarters of the eventual local recurrence risk occurred during the first 5 years. In the
comparisons that involved little (�10%) difference in 5-year local recurrence risk there was little difference in
15-year breast cancer mortality. Among the 25 000 women in the comparisons that involved substantial (�10%)
differences, however, 5-year local recurrence risks were 7% active versus 26% control (absolute reduction 19%), and
15-year breast cancer mortality risks were 44·6% versus 49·5% (absolute reduction 5·0%, SE 0·8, 2p�0·00001).
These 25 000 women included 7300 with breast-conserving surgery (BCS) in trials of radiotherapy (generally just to
the conserved breast), with 5-year local recurrence risks (mainly in the conserved breast, as most had axillary
clearance and node-negative disease) 7% versus 26% (reduction 19%), and 15-year breast cancer mortality risks
30·5% versus 35·9% (reduction 5·4%, SE 1·7, 2p=0·0002; overall mortality reduction 5·3%, SE 1·8, 2p=0·005).
They also included 8500 with mastectomy, axillary clearance, and node-positive disease in trials of radiotherapy
(generally to the chest wall and regional lymph nodes), with similar absolute gains from radiotherapy; 5-year local
recurrence risks (mainly at these sites) 6% versus 23% (reduction 17%), and 15-year breast cancer mortality risks
54·7% versus 60·1% (reduction 5·4%, SE 1·3, 2p=0·0002; overall mortality reduction 4·4%, SE 1·2, 2p=0·0009).
Radiotherapy produced similar proportional reductions in local recurrence in all women (irrespective of age or
tumour characteristics) and in all major trials of radiotherapy versus not (recent or older; with or without systemic
therapy), so large absolute reductions in local recurrence were seen only if the control risk was large.
To help assess the life-threatening side-effects of radiotherapy, the trials of radiotherapy versus not were combined
with those of radiotherapy versus more surgery. There was, at least with some of the older radiotherapy regimens, a
significant excess incidence of contralateral breast cancer (rate ratio 1·18, SE 0·06, 2p=0·002) and a significant
excess of non-breast-cancer mortality in irradiated women (rate ratio 1·12, SE 0·04, 2p=0·001). Both were slight
during the first 5years, but continued after year 15. The excess mortality was mainly from heart disease (rate ratio
1·27, SE 0·07, 2p=0·0001) and lung cancer (rate ratio 1·78, SE 0·22, 2p=0·0004).
Interpretation In these trials, avoidance of a local recurrence in the conserved breast after BCS and avoidance of a
local recurrence elsewhere (eg, the chest wall or regional nodes) after mastectomy were of comparable relevance to
15-year breast cancer mortality. Differences in local treatment that substantially affect local recurrence rates would,
in the hypothetical absence of any other causes of death, avoid about one breast cancer death over the next 15years
for every four local recurrences avoided, and should reduce 15-year overall mortality